A congressional lawmaker is investigating the role that a former Gilead Sciences (GILD) lobbyist played in the Trump administration and its efforts to develop a payment model for a pricey new Novartis cancer drug.
The focus of the inquiry is Joseph Grogan, who joined the Trump administration in early 2017 as associate director of health programs at the Office of Management and Budget, where he was working on a “pay-for-performance” program for the Novartis (NVS) drug, called Kymriah.
About the Author Reprints
I wonder if there are viaticals for cancer treatments , which have a chance of success, as it was for HIV patients who are, as we are yet without a cure, going to die?